For the second quarter of 2010, the company has generated net income of $16.83m, compared to $3.45m for the same period in 2009.
Parexel’s income from operations was $28.2m, compared to $18.71m for the same period in 2009.
For the six months ended 31 December 2010, the company posted total revenue of $706.3m, compared to $645.52m for the same period in 2009.
Net income was $34.62m for the six months of 2010, compared to $15.89m for the same period in 2009, However, the company’s income from operations was $58.2m, compared to $37.19m for the same period in 2009.
Parexel chairman and CEO Josef von Rickenbach said during the second quarter, Parexel delivered year-over-year revenue growth in all three business segments, and earnings per share that were in line with our expectations.
"New business wins and moderate cancellations culminated in record backlog of over $3bn. We also experienced a notable increase in proposals from small and emerging biopharma clients during the quarter," Rickenbach said.